
血液・膠原病・感染症内科学講座

【研究プロジェクト名および概要】

- I. ヒト T 細胞白血病ウイルス 1 型 (HTLV-1) の発がん機構
- II. 成人 T 細胞白血病 (ATL) の臨床、病態解析と治療開発
- III. 白血病の発症機構に基づく病態研究と新しい治療法の開発
- IV. 悪性リンパ腫、骨髄腫および原発性アミロイドーシスの病態解析と新規治療法開発へ向けたトランスレーショナルリサーチ
- V. 膠原病・自己免疫疾患の病態解析と治療
- VI. 後天性免疫不全症候群 (AIDS) の病態解析とその分子標的治療剤開発へ向けたトランスレーショナルリサーチ
- VII. 発作性夜間ヘモグロビン尿症 (PNH) や慢性骨髄性白血病 (CML) などの造血幹細胞疾患の臨床及び基礎研究
- VIII. 血液凝固系の臨床及び基礎研究

【教職員および大学院学生】

教授	安永 純一郎
助 教	河野 和
助 教	遠藤 慎也
助 教	七條 敬文
大学院 (博士課程)	上野 満徳
大学院 (博士課程)	園田 未祐
大学院 (博士課程)	IDRISS OSAMA MOHAMMED ALI HUSSEIN
大学院 (博士課程)	張 文怡
大学院 (博士課程)	白 俊哲
大学院 (博士課程)	MAHDI YASSER ELTEGANI HAMED
大学院 (博士課程)	岡本 祐毅
大学院 (博士課程)	坂田 亮
大学院 (博士課程)	陳 学達
大学院 (博士課程)	中村 貴久
技術補佐員	松本 美穂
技術補佐員	西銘 由美

【研究プロジェクト】

I, II, III, IV, V, VI, VII, VIII
IV
II, IV
I, II, III, IV
I, II
I, II
I, II
I, II
IV
I, II
I, II
I, II
I, II
I, II
I, II
I, II
I, II

【連絡先】 電話：096-373-5156 FAX：096-373-5158

【ホームページ】 <https://2naika.jp/>

【特殊技術・特殊装置】

- 1. P3 施設
- 2. Flow cytometer (FACSVerse, FACSLytic)
- 3. Confocal microscope
- 4. Next-generation sequencer (Illumina Miseq)
- 5. Cell sorter (SONY SH800S)

【英文原著】

- 1. Watanabe M, Yasunaga JI, Hussein O, Tanaka A, Shichijo T, Izaki M, Komohara M, Matsuoka.
A dendritic cell-like transition of T cells is associated with spontaneous remission of adult T-cell leukemia-lymphoma. Cancer Immunol Res., In press.
- 2. Shichijo T, Yasunaga JI.
Stratagems of HTLV-1 for persistent infection and the resultant oncogenesis: Immune evasion and clonal expansion. Leuk Res., In press.
- 3. Yamada R, Arima K, Yano H, Fujiwara Y, Yamashita K, Kanemitsu K, Hanada N, Yasunaga JI, Iwatsuki M, Mikami Y, Komohara Y.
Impact of HTLV-1 infection on clinicopathological characteristics and tumour immune microenvironment in colorectal cancer. Virchows Arch.

4. Kidiga M, Murata M, Grover P, Ode H, Iwatani Y, Seki Y, Kuramitsu M, Morimoto M, Natsume T, Kaneko A, Hayashi S, Yasunaga JI, Matsuoka M, Mizukami T, Akari H.
Identification of occult STLV-1 infection in Japanese macaques. *J Infect Dis.* jiaf120. doi: 10.1093/infdis/jiaf120, 2025
5. Liu B, Yasunaga JI, Liang Y, Zhou R, Yang S, Yuan X, Liu J, Zuo X, Miura M, Higuchi Y, Matsumoto T, Toyoda K, Matsuoka M, Ma G.
Identification of AK4 and RHOC as potential oncogenes addicted by adult T cell leukemia. *Proc Natl Acad Sci U S A.* 25;122(8):e2416412122, 2025
6. Yamamura A, Nosaka K, Tatetsu H, Yasunaga JI.
Successful treatment with EPOCH followed by mogamulizumab for angioimmunoblastic T-cell lymphoma with myelofibrosis and pure red cell aplasia. *Rinsho Ketsueki.*66(1):24-29, 2025
7. Grover P, Murata M, Kidiga M, Hayashi S, Ode H, Iwatani Y, Morimoto M, Natsume T, Kaneko A, Yasunaga JI, Matsuoka M, Kuramitsu M, Seki Y, Mizukami T, Akari H.
Identification of natural remission of mother-to-child retroviral transmission. *J Infect Dis.* jiaf064, 2025
8. Tanaka A, Ishitsuka Y, Ohta H, Takenouchi N, Nakagawa M, Koh KR, Onishi C, Tanaka H, Fujimoto A, Yasunaga JI, Matsuoka M.
Integrative analysis of ATAC-seq and RNA-seq for cells infected by human T-cell leukemia virus type 1. *PLoS Comput Biol.* 21(1):e1012690, 2025
9. Utsunomiya A, Yasunaga JI, Tabuchi T, Nakano N, Odawara J, Kubota A, Tokunaga M, Miyazono T, Matsuoka M, Ito Y, Tashiro Y.
A 25-year clonal resurrection in adult T-cell leukemia-lymphoma relapse. *Int J Hematol.*121(3):416-420, 2025
10. Maruyama D, Jacobsen E, Porcu P, Allen P, Ishitsuka K, Kusumoto S, Narita T, Tobinai K, Foss F, Tsukasaki K, Feldman T, Imaizumi Y, Izutsu K, Morishima S, Yamauchi N, Yuda J, Brammer JE, Kawamata T, Ruan J, Nosaka K, Utsunomiya A, Wang J, Zain J, Kakurai Y, Yamauchi H, Hizukuri Y, Biserna N, Tachibana M, Inoue A, Horwitz SM.
Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multi-centre, open-label, single-arm, phase 1 study. *Lancet Oncol.* 25(12):1589-1601, 2024
11. Endo S, Nishimura N, Toyoda K, Komohara Y, Carreras J, Yuki H, Shichijo T, Ueno S, Ueno N, Hirata S, Kawano Y, Nosaka K, Miyaoka M, Nakamura N, Sato A, Ando K, Mitsuya H, Akashi K, Tenen DG, Yasunaga JI, Matsuoka M, Okuno Y, Tatetsu H.
Decreased PU.1 expression in mature B cells induces lymphomagenesis. *Cancer Sci.* 115(12):3890-3901, 2024
12. Izutsu K, Ando K, Nishikori M, Shibayama H, Goto H, Kuroda J, Kato K, Imaizumi Y, Nosaka K, Sakai R, Abe M, Hojo S, Nakanishi T, Rai S.
Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study. *Int J Hematol.* 120(5):621-630, 2024
13. Kusumoto S, Munakata W, Machida R, Terauchi T, Onaya H, Oguchi M, Iida S, Nosaka K, Suzuki Y, Harada Y, Miyazaki K, Maruta M, Fukuhara N, Toubai T, Kubota N, Ohmachi K, Saito T, Rai S, Mizuno I, Fukuhara S, Takeuchi M, Tateishi U, Maruyama D, Tsukasaki K, Nagai H.
Interim PET-guided ABVD or ABVD/escalated BEACOPP for newly diagnosed advanced-stage classic Hodgkin lymphoma (JCOG1305). *Cancer Sci.* 115(10):3384-3393, 2024
14. Nakamura T, Tatetsu H, Higuchi Y, Endo S, Shiraishi S, Kawanaka K, Imakane D, Sonoda M, Furuta R, Shichijo T, Honda Y, Karube K, Mikami Y, Nosaka K, Matsuoka M, Yasunaga JI.
Extranodal NK/T-cell lymphoma with localized relapse in bone marrow of lower leg detected using PET-CT. *J Clin Exp Hematop.*64(1):45-51, 2024
15. Shichijo T, Yasunaga JI, Sato K, Nosaka K, Toyoda K, Watanabe M, Zhang W, Koyanagi Y, Murphy EL, Bruhn RL, Koh KR, Akari H, Ikeda T, Harris RS, Green PL, Matsuoka M.
Vulnerability to APOBEC3G linked to the pathogenicity of deltaretroviruses. *Proc Natl Acad Sci U S A.* 121(13):e2309925121, 2024
16. Yamada A, Yasunaga JI, Liang L, Zhang W, Sunagawa J, Nakaoka S, Iwami S, Kogure Y, Ito Y, Kataoka K, Nakagawa M, Iwanaga M, Utsunomiya A, Koh KR, Watanabe T, Nosaka K, Matsuoka M.
Anti-HTLV-1 immunity combined with proviral load as predictive biomarkers for adult T-cell leukemia-lymphoma. *Cancer Sci.* 115(1):310-320, 2024
17. Iriyama N, Iwanaga E, Kimura Y, Watanabe N, Ishikawa M, Nakayama H, Sato E, Takayuki T, Mitsumori T, Takaku T, Nakazato T, Tokuhira M, Fujita H, Ando M, Hatta Y, Kawaguchi T.
Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study

Group. *Int J Hematol.* 2024;120:60.

18. Morikawa K, Izumiya Y, Takashio S, Kawano Y, Oguni T, Kuyama, N, Oike F, Yamamoto M, Tabata N, Ishii M, Hanatani S, Hoshiyama T, Kanazawa H, Matsuzawa Y, Usuku H, Yamamoto E, Ueda M, Tsujita K. Early experience with daratumumab-containing regimens in patients with light-chain cardiac amyloidosis. *Journal of Cardiology* (in press)
19. Yamamoto T, Furukawa A, Zhou Y, Kono N, Kitajima S, Ohguchi H, Kawano Y, Ito S, Araki N, Ohtsuki S, Masuda T. Increased CSN5 expression enhances the sensitivity to lenalidomide in multiple myeloma cells. *iScience* 27(12): 111399, 2024
20. Nishimura N, Kawano Y, Yasunaga JI. Carfilzomib and dexamethasone in multiple myeloma patients refractory to anti-CD38 monoclonal antibodies. *International Journal of Myeloma* 14(5): 42-46, 2024
21. Kawano Y, Nishimura N, Yasunaga JI. Serum monoclonal immunoglobulin light chain detection differs between immunofixation electrophoresis methods in patients with AL amyloidosis. *International Journal of Hematology* 120(2):212-216, 2024
22. Ohguchi H, Ohguchi Y, Kubota S, Etoh K, Hamashima A, Usuki S, Yokomizo-Nakano T, Bai J, Masuda T, Kawano Y, Harada T, Nakao M, Minami T, Hideshima T, Araki K, Sashida G. Multiple myeloma-associated DIS3 gene is essential for hematopoiesis but loss of DIS3 is insufficient for myelomagenesis. *Blood Neoplasia* 1 (1): 100005, 2024
23. Usuku H, Yamamoto E, Sueta D, Shinriki R, Oike F, Tabata N, Ishii M, Hanatani S, Hoshiyama T, Kanazawa H, Arima Y, Takashio S, Kawano Y, Oda S, Kawano H, Ueda M, Tsujita K. A New Staging System Using Right Atrial Strain in Patients with Immunoglobulin Light-Chain Cardiac Amyloidosis. *ESC Heart Failure* 11: 1612-1624, 2024
24. Oda K, Hayashi H, Yamamoto K, Kondo S, Katanoda T, Okamoto S, Miyakawa T, Iwanaga E, Nosaka K, Kawaguchi T, Nakata H. Antibiotic spectrum coverage scoring as a potential metric for evaluating the antimicrobial stewardship team activity: a single-center study. *Infect Control Hosp Epidemiol.* 45(11):1-9, 2024
25. Oda K, Okamoto S, Iwanaga E, Nakata H. Investigating the WHO's AWaRe classification for assessing antimicrobial stewardship programs: A single-center study. *J Infect Chemother.* (1):102511, 2025
26. Oda K, Yamaguchi A, Matsumoto N, Nakata H, Higuchi Y, Nosaka K, Jono H, Saito H. Dose Individualization of Cefepime for Febrile Neutropenia in Patients with Lymphoma or Multiple Myeloma: Implications for Therapeutic Drug Monitoring. *Ther Drug Monit.* 46(1):80-88, 2024
27. Nakamura T, Yoshinouchi T, Okumura M, Yokoyama T, Mori D, Nakata H, Yasunaga JI, Tanaka Y. Diverse antifungal potency of terbinafine as a therapeutic agent against *Exophiala dermatitidis* in vitro. *Sci Rep.* 14(1):27500, 2024
28. Nakamura T, Uchiba M, Nakata H, Mizumoto T, Beppu T, Matsushita S. Partial Splenic Embolization in a Patient with Hemophilia A and Severe Thrombocytopenia: A Case Report. *Hematol Rep.* 2024 Mar 26;16(2):185-192. doi: 10.3390/hematolrep16020019
29. Yamakawa K, Okamoto K, Seki Y, Ikezoe T, Ito T, Iba T, Gando S, Ushio N, Totoki T, Wada T, Asakura H, Ishikura H, Uchiba M, Uchiyama T, Kawasaki K, Kawano N, Kushimoto S, Koga S, Sakamoto Y, Tamura T, Nishio K, Hayakawa M, Matsumoto T, Madoiwa S, Mayumi T, Yamada S, Wada H; Committee of the Clinical Practice Guidelines for Management of Disseminated Intravascular Coagulation 2024, the Japanese Society on Thrombosis and Hemostasis. Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 1: sepsis. *Int J Hematol.* doi: 10.1007/s12185-024-03896-9. Online ahead of print.
30. Kawano N, Ikezoe T, Seki Y, Yamakawa K, Okamoto K, Fukatsu M, Madoiwa S, Uchiyama T, Asakura H, Yamada S, Koga S, Ishikura H, Ito T, Iba T, Uchiba M, Kawasaki K, Gando S, Kushimoto S, Sakamoto Y, Tamura T, Nishio K, Hayakawa M, Matsumoto T, Mayumi T, Wada H; Committee of the Clinical Practice Guidelines for Disseminated Intravascular Coagulation 2024, the Japanese Society on Thrombosis and Hemostasis. Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 2: hematologic malignancy. *Int J Hematol.* doi:10.1007/s12185-024-03887-w. Online ahead of print.
31. Seki Y, Okamoto K, Ikezoe T, Yamakawa K, Madoiwa S, Uchiyama T, Asakura H, Yamada S, Koga S, Ishikura H, Ito

T, Iba T, Uchiba M, Kawasaki K, Kawano N, Gando S, Kushimoto S, Sakamoto Y, Tamura T, Nishio K, Hayakawa M, Matsumoto T, Mayumi T, Wada H; Committee of the Clinical Practice Guidelines for Disseminated Intravascular Coagulation 2024, the Japanese Society on Thrombosis and Hemostasis.

Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 3: solid cancers and vascular abnormalities. Int J Hematol.doi: 10.1007/s12185-024-03912-y.Online ahead of print.

32. Hayakawa M, Seki Y, Ikezoe T, Yamakawa K, Okamoto K, Kushimoto S, Sakamoto Y, Itagaki Y, Takahashi Y, Ishikura H, Mayumi T, Tamura T, Nishio K, Kawazoe Y, Shigeno A, Takatani Y, Tampo A, Nakamura Y, Mochizuki K, Yada N, Kawasaki K, Kiyokawa A, Morikawa M, Uchiba M, Matsumoto T, Asakura H, Madoiwa S, Uchiyama T, Yamada S, Koga S, Ito T, Iba T, Kawano N, Gando S, Wada H; Committee of the Clinical Practice Guidelines for Disseminated Intravascular Coagulation 2024, the Japanese Society on Thrombosis, Hemostasis.
Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024: part 4-trauma, burn, obstetrics, acute pancreatitis/liver failure, and others. Int J Hematol. doi: 10.1007/s12185-025-03918-0.Online ahead of print.
33. Usuku H, Yamamoto E, Sakata K, Hirata S, Toda A, Oike F, Tabata N, Ishii M, Hanatani S, Hoshiyama T, Sueta D, Kanazawa H, Arima Y, Takashio S, Matsuzawa Y, Kawano H, Yasunaga JI, Tsujita K. Usefulness of platelet count to predict concomitant valvular heart disease in patients with systemic lupus erythematosus. Int J Cardiol Heart Vasc.53:101420, 2024
34. Kaneko K, Suto M, Miyagawa E, Mikami M, Nakamura Y, Murashima A, Takehara K. Preconception underweight impact on postnatal osteoporotic fracture: a retrospective cohort study using Japanese claims data. BMC Pregnancy Childbirth.24(1):315, 2024
35. Maeshima K, Abe T, Imada C, Ozaki T, Shibata H. Anifrolumab for refractory lupus erythematosus panniculitis in systemic lupus erythematosus. Rheumatology (Oxford).63(3):e115-e117, 2024
36. Ozaki T, Imada C, Shirakami K, Abe T, Shingai Y, Umeki T, Fukuda A, Ishii K, Shibata H. Serum Soluble Interleukin-2 Receptor as a Potential Marker for Assessing Disease Activity in the TAFRO Subtype of Idiopathic Multicentric Castleman Disease. Intern Med, 2025

【和文総説】

1. 河野和
アミロイドーシス
血液内科 89(4):398-403, 2024
2. 内場光浩
鉄代謝の基礎. 生体内の鉄代謝
臨床婦人科産科 78(7), 566-571, 2024
3. 園木孝志, 蒸野寿紀, 上田恭典, 上野志貴子, 大石晃嗣, 大崎浩一, 熊川みどり, 末岡榮三朗, 長井一浩, 横濱章彦, 松本雅則
科学的根拠に基づいた赤血球製剤の使用ガイドライン (改訂第3版)
日本輸血細胞治療学会誌 70 (6):579-596, 2024
4. 梅木達仁, 尾崎貴士, 安部佑, 今田千晴, 首藤航太, 大村雄一, 堀田美鈴, 安倍いとみ, 森山かおり, 織部元廣, 石井宏治, 柴田洋孝
「再発性多発軟骨炎に伴う辺縁系脳炎の臨床的特徴〜Case Based Review〜」
大分県医学会雑誌 第31巻:80-86, 2024
5. 七條敬文
「Polatuzumab vedotin治療におけるcell-of-originの意義」血液内科 88(4):412-418, 2024
6. 七條敬文, 安永純一郎
「ATLLの初回治療方針」EBM血液疾患の治療2025-2026, 2024
7. 北川内優佳, 竹村侑紀, 福嶋理香, 石原綾子, 横山俊朗, 中村朋文, 松岡雅雄, 田中靖人
(1→3)-β-D-グルカン測定試薬「β-グルカンシングルM30テストワコー」の基礎的検討
医学検査 73(2):271-277, 2024
8. 福本政和, 林秀幸, 芳之内達也, 水田加奈子, 山本景一, 横山俊朗, 中村朋文, 田中靖人
GeneXpert®システムを用いて迅速に報告し得た多剤耐性Mycobacterium tuberculosisの1症例
くまもと検査医学 13 6-8, 2024